Songjiang Ma Sells 1,057 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 1,057 shares of the business’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14. Following the sale, the president now directly owns 2,915,194 shares in the company, valued at approximately $29,210,243.88. The trade was a 0.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $565.60.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Stock Down 1.2 %

Shares of GYRE opened at $10.80 on Friday. The stock’s 50-day moving average price is $11.74 and its two-hundred day moving average price is $12.65. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $26.37.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC increased its position in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares during the period. Geode Capital Management LLC boosted its stake in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the last quarter. State Street Corp increased its position in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the period. FMR LLC bought a new position in Gyre Therapeutics during the third quarter worth $47,000. Finally, Advantage Alpha Capital Partners LP acquired a new position in Gyre Therapeutics in the third quarter valued at $334,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.